Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.36 |
| ▸ | ITGAL | P20701 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956451 | 0.88 | UGT2B7 (0.34) | EPHX2POLBPTPN2PTPN1MAPT | |
| SCHEMBL956449 | 0.88 | UGT2B7 (0.34) | EPHX2POLBPTPN2PTPN1MAPT | |
| SCHEMBL18472141 | 0.87 | EPHX2 (0.41) | EPHX2POLBSMN1; SMN2MAPT | |
| SCHEMBL957349 | 0.86 | MAPT (0.31) | EPHX2MAPT | |
| SCHEMBL957348 | 0.86 | MAPT (0.31) | EPHX2MAPT | |
| SCHEMBL957356 | 0.83 | RAB9A (0.40) | TDP1SMN1; SMN2 | |
| SCHEMBL957354 | 0.83 | RAB9A (0.40) | TDP1SMN1; SMN2 | |
| SCHEMBL18472125 | 0.79 | EPHX2 (0.37) | EPHX2CYP1A2TDP1ITGB2ICAM1 | |
| SCHEMBL18472109 | 0.79 | EPHX2 (0.37) | EPHX2CYP1A2TDP1ITGB2ICAM1 | |
| SCHEMBL18465429 | 0.79 | EPHX2 (0.37) | EPHX2CYP1A2TDP1ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS INC. (US) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, UACA | EPHX2 3970/4885CYP1A2 4582/4885TDP1 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.